Watching Longeveron; Zacks Small-Cap Research Issues $15.10 Price Valuation; Says Longeveron Is Focusing On Using Its Primary Treatment, Lomecel-B, To Fight A Rare Pediatric Heart Birth Defect That Devastates Families; Announced The Completion Of An Encouraging Meeting With Investigators Involved In The Ongoing Trial Of Lomecel-B For The Treatment Of HLHS
Portfolio Pulse from Benzinga Newsdesk
Zacks Small-Cap Research has issued a $15.10 price valuation for Longeveron (LGVN), highlighting the company's focus on using its primary treatment, Lomecel-B, to combat a rare pediatric heart birth defect. Longeveron also announced the completion of a promising meeting with investigators involved in the ongoing trial of Lomecel-B for treating HLHS.
June 12, 2024 | 3:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zacks Small-Cap Research has issued a $15.10 price valuation for Longeveron, emphasizing the company's focus on Lomecel-B for treating a rare pediatric heart defect. The completion of a promising meeting with trial investigators is a positive development.
The $15.10 price valuation from Zacks Small-Cap Research is a positive signal for investors, indicating confidence in Longeveron's potential. The focus on Lomecel-B for a rare pediatric heart defect and the completion of a promising meeting with trial investigators further support a positive short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100